Search Results

FDA

QOL Medical, LLC receives FDA approval of Sucraid® (sacrosidase) Oral Solution single-use containers for patients with Congenital Sucrase-Isomaltase Deficiency (CSID)

QOL Medical, LLC, a ground-breaking, rare disease pharmaceutical company, announced today that the United States (U.S.) Food & Drug Administration (FDA) approved Sucraid® single-use containers for patients more than 33 lb (15 kg) with Congenital Sucrase-Isomaltase Deficiency (CSID).

September 6, 2022

·

3 min read

Business

QOL Medical, LLC Selects Optum Frontier Therapies as an Exclusive Pharmacy Partner to Best Support Congenital Sucrase-Isomaltase Deficiency (CSID) Patients on Sucraid® (sacrosidase) Oral Solution

QOL Medical, LLC announced today it has selected Optum Frontier Therapies as its new pharmacy partner to support CSID patients nationwide being treated with Sucraid® (sacrosidase) Oral Solution.

April 15, 2022

·

4 min read

Press Releases

Tenon Medical(R) to Host Meetings During the 2025 J.P. Morgan Healthcare Conference in San Francisco

January 9, 2025

·

2 min read

Genetown

Eisai Presented New Analyses of ARIA and QOL on Lecanemab in Clarity AD at the AD/PD™ 2023 Annual Meeting

Eisai Co., Ltd. and Biogen Inc. announced that Eisai presented new analyses on amyloid-related imaging abnormalities with the use of antiplatelet and anticoagulant medications, isolated ARIA-H, and caregiver burden and health-related quality of life, from the results of Eisai’s Phase 3 Clarity AD study of lecanemab, an anti-amyloid-β protofibril* antibody, at the 2023 International Conference on Alzheimer’s and Parkinson’s Diseases annual meeting AD/PD™.

March 30, 2023

·

13 min read

Press Releases

Tenon Medical(R) Regains Full Compliance with Nasdaq Continued Listing Requirements

October 28, 2024

·

3 min read

News

Tenon Medical(R) Announces Issuance of Three U.S. Patents

October 18, 2024

·